Drug Profile
Research programme: microRNA therapeutics - Regulus Therapeutics/Sanofi
Alternative Names: anti-miR-21; microRNA-21 therapeutics; microRNA-221/microRNA-222 therapeutics; miR-221/222 therapeutics; miRNA-21 therapeuticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Regulus Therapeutics; sanofi-aventis
- Developer Regulus Therapeutics; Sanofi
- Class MicroRNAs; Oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Nephritis
- No development reported Fibrosis; Liver cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in liver cancer in USA
- 13 Feb 2014 Regulus Therapeutics and Sanofi renew agreement to co-develop microRNA therapeutics for Fibrosis and Cancer